In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...
A computational model of the more than 26 million atoms in a DNA-packed viral capsid expands our understanding of virus structure and DNA dynamics, insights that could provide new research avenues and ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
Because viruses have to hijack someone else’s cell to replicate, they’ve gotten very good at it—inventing all sorts of tricks. A new study from two University of Chicago scientists has revealed how ...
A study by chemists at the University of Chicago has uncovered a new key step in the process that HIV uses to replicate itself. The study, published Jan. 6 in Science Advances, used computer modeling ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...